Initiated in January 2010, the ADVANCE-ON study is the post-interventional observational study of ADVANCE. It is meant to determine the long term effects of the ADVANCE interventions. Medpharmgene is responsible for the follow up of the Canadian patients. As for ADVANCE, Medpharmgene has developed the protocol for a genetic sub-study named ADVANCE-ON Genes. In partnership with Prognomix, we collect the additional DNA samples required to analyze the epigenetic and telomeric length changes that occur over time with the objective of determining the relationship between these changes and clinical events.

We are thankful to all Canadian investigators and coordinators for their contribution to ADVANCE-ON trial:

LMC Endocrinology Centres LTD : B. Binder, S. Ross, L. Visvanatha
Centre de recherche clinique de Laval : A. Bélanger, R. Dumas, S. Gauthier
Centre de recherche d’endocrinologie, Sherbrooke : C. Godin, C. Lachance, B. St-Pierre
Centre hospitalier universitaire de Sherbrooke : M-F. Langlois, P. Maheux, J. Guillemette
Centre hospitalier de l’Université de Montréal : J-L. Chiasson, J. Doucet, P. Hamet, H. L angelier, M. Nelson
Institut universitaire de cardiologie et de pneumologie de Québec : M. Bolduc, F. Dubé, D. Garceau, C. Garceau, I. Kirouac, M-C. Landcop, L. Mercier, K. Raby
Capital Health District Authority, Halifax : D. Clayton, G. McCarthy
St. Joseph’s Health Centre, London : L. Bere, R. McManus
University of Toronto : D. Bédard, R. Josse, L. Leiter - canadian online casinos